క్యాన్సర్ సైన్స్ & థెరపీ

Long-Term Complete Remission of Refractory Primary Cutaneous Anaplastic Large T Cell Lymphoma Treated with Brentuximab Vedotin: A Case Report

Abstract

Loseto G, Ciavarella S, Scattone A, Calabrese A, Quinto AM, Guarini A

Based on early results from a single phase III trial, Brentuximab Vedotin (BV), a drug-conjugated anti-CD30 monoclonal antibody, is changing the treatment strategy, especially for relapsed/refractory cutaneous anaplastic large cell lymphomas (cALCL) patients with limited therapeutic options. However, despite high response rates registered in this setting, follow-up data about duration of response and long-term toxicity profile are still lacking. Here, we report a case of refractory, advanced stage cALCL in a 78-year old patient with poor prognosis, which showed a dramatic, long-lasting response even to reduced doses of BV as salvage treatment.